VIVUS — Technical Presentation (June 2010)
20 slides from VIVUS's technical presentation, Jun 21, 2010
Slide 1: Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight
W. Timothy Garvey, MD Chair, Department of Nutrition Sciences Professor of Nutrition Sciences University of Alabama at Birmingham Staff Physician and GRECC Investigator Birmingham Veterans Affairs Medical Center Birmingham, Alabama Charles H. Bowden, MD Barbara Troupin, MD Wesley W. Day, PhD Vivus,
Slide 2: Disclosures
Disclosures Dr. Garvey has the following financial relationships to disclose: Research support – Merck & Co., Inc.; Isis/Genzyme; Amylin Pharmaceuticals Speakers Bureau – Merck & Co., Inc; Abbott Nutrition Advisor/consultant – Daiichi-Sankyo; Tethys; Vivus, Inc. Board member – Daiichi-Sankyo, Tethys
Slide 3: Obesity: An Escalating Public Health Issue
Obesity: An Escalating Public Health Issue Obesity is associated with significantly increased morbidity, mortality related to cardiovascular disease, diabetes1,2 Potential health benefits from reduction in obesity are of considerable public health importance3 10% initial weight loss is recommended g
Slide 4: Phentermine and Topiramate
Phentermine and Topiramate Phentermine (PHEN)1 FDA-approved (1959) as a short-term adjunct to diet and exercise Acts primarily through appetite suppression Topiramate (TPM) Neurotherapeutic agent approved for seizure disorders (1996) and migraine headache prophylaxis (2004)2 Demonstrated weight loss
Slide 5: PHEN/TPM CR is an investigational, fixed-dose combination weight-loss therapy
PHEN/TPM CR is an investigational, fixed-dose combination weight-loss therapy PHEN and TPM have demonstrated weight loss through different mechanisms1 Greater response seen with combination than with either agent alone, allowing for lower doses of each agent1 Complementary mechanisms may reduce/coun
Slide 6: CONQUER: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
CONQUER: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial PHEN/TPM CR 7.5/46 mg or 15/92 mg vs placebo 56 weeks of treatment in overweight/obese adults with >2 weight-related comorbidities BMI >27 kg/m2 to <45 kg/m2* Comorbidities include: Dyslipidemia (elevated trig
Slide 7: Outcomes of Interest
Outcomes of Interest Primary endpoints: Mean percent weight loss at Week 56 Percentage of subjects losing >5% of body weight at Week 56 Secondary/other endpoints included: Percentage of subjects losing >10% of body weight at Week 56 Changes in cardiometabolic markers Lipids Glycemic parameters Infla
Slide 8: CONQUER Study Design
CONQUER Study Design Dosing and Randomization Placebo (n=994) PHEN/TPM CR 7.5/46 (n=498) PHEN/TPM CR 15/92 (n=995) Total (N=2487)
Slide 9: Baseline Demographics
Baseline Demographics Placebo (n=994) PHEN/TPM CR 7.5/46 (n=498) 15/92 (n=995) Age (years), mean (SD) 51.2 (10.3) 51.1 (10.4) 51.0 (10.7) Female, n (%) 695 (69.9) 349 (70.1) 693 (69.6) Race Caucasian 86.6% 86.1% 85.4% African 11.5% 11.2% 12.3% Weight (kg), mean (SD) 103.3 (18.1) 102.6 (18.2) 103.0 (
Slide 10: Mean Percent Weight Loss
Mean Percent Weight Loss at Week 56: ITT-LOCF, Study Completers *P<0.0001 vs placebo
Slide 11: Subjects With >5% Weight Loss
Subjects With >5% Weight Loss at Week 56: ITT-LOCF, Study Completers *P<0.0001 vs placebo ITT-LOCF Study Completers 20.8% 26.2% 62.1%* 74.6%* 70.0%* 85.1%* 0 10 20 30 40 50 60 70 80 90 ITT-LOCF Study Completers % of Subjects
Slide 12: Subjects With >10% Weight Loss
Subjects With >10% Weight Loss at Week 56: ITT-LOCF, Study Completers *P<0.0001 vs placebo ITT-LOCF Study Completers
Slide 13: Change (%) in Lipid Parameters
Change (%) in Lipid Parameters at Week 56: ITT-LOCF *P<0.05 vs placebo TC LDL-C HDL-C TG Baseline Mean (mg/dL): 206 201 205 124 120 124 49 49 49 164 161 162
Slide 14: Changes in Glycemic Parameters
Changes in Glycemic Parameters at Week 56: ITT-LOCF Baseline Mean 106.6 106.2 105.7 5.9 5.9 5.9 n: 938 473 954 805 449 895 Fasting Glucose (mg/dL) HbA1c (%) *P<0.005 vs placebo
Slide 15: Changes in Insulinemic Parameters
Changes in Insulinemic Parameters at Week 56: ITT-LOCF Fasting Insulin (uIU/mL) HOMA-IR *P<0.001 vs placebo 15 Baseline Mean 17.8 18.0 18.4 5.2 4.9 5.3 n: 925 464 937 925 464 937
Slide 16: Changes in hsCRP, Adiponectin
Changes in hsCRP, Adiponectin at Week 56: ITT-LOCF Baseline mean: 6.4 7.0 6.5 8.0 8.1 7.9 n: 777 440 880 737 419 836 *P<0.0001 vs placebo hsCRP=high-sensitivity C-reactive protein hsCRP (mg/L) Adiponectin (ug/mL)
Slide 17: Changes in Fibrinogen
Changes in Fibrinogen at Week 56: ITT-LOCF Baseline mean: 459.6 459.6 454.4 n: 737 416 842 *P<0.05 vs placebo Fibrinogen (mg/dL)
Slide 18: Treatment-Emergent Adverse Events Reported in >5% of CONQUER Subjects
Treatment-Emergent Adverse Events (AEs) Reported in >5% of CONQUER Subjects: Safety Set Adverse Event (Preferred Term) Placebo (n=993) (%) 7.5/46 (n=498) (%) 15/92 (n=994) (%) Dry mouth 2.4 13.5 20.8 Paresthesia 2.0 13.7 20.5 Constipation 5.9 15.1 17.4 Upper respiratory tract infection 12.9 12.2 13.
Slide 19: Safety Summary
Safety Summary Most AEs were mild/moderate in severity Similar incidences of AEs by severity across treatment groups Treatment-emergent serious AEs comparable: 3.8% in placebo vs 3.8% in all PHEN/TPM CR Discontinuation rates due to treatment-emergent AEs: 8.9% for placebo 11.6% for 7.5/46 19.2% for
Slide 20: Conclusions
Conclusions PHEN/TPM CR led to significant weight loss vs placebo at 56 weeks PHEN/TPM CR improved all measured cardiometabolic risk factors – lipid, glycemic, inflammatory, coagulation factors Greater weight loss seen with the 15/92 dose was associated with greater improvements in important risk ma